- Home
- EVOK vs XXII Comparison
EVOK vs XXII Comparison
Compare EVOK & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- XXII
- Stock Information
- Founded
- EVOK 2007
- XXII 1998
- Country
- EVOK United States
- XXII United States
- Employees
- EVOK N/A
- XXII N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- XXII Medicinal Chemicals and Botanical Products
- Sector
- EVOK Health Care
- XXII Health Care
- Exchange
- EVOK Nasdaq
- XXII Nasdaq
- Market Cap
- EVOK 5.4M
- XXII 6.2M
- IPO Year
- EVOK 2013
- XXII N/A
- Fundamental
- Price
- EVOK N/A
- XXII $1.58
- Analyst Decision
- EVOK
- XXII
- Analyst Count
- EVOK 0
- XXII 0
- Target Price
- EVOK N/A
- XXII N/A
- AVG Volume (30 Days)
- EVOK 30.7K
- XXII 3.6M
- Earning Date
- EVOK 11-06-2025
- XXII 11-11-2025
- Dividend Yield
- EVOK N/A
- XXII N/A
- EPS Growth
- EVOK N/A
- XXII N/A
- EPS
- EVOK N/A
- XXII N/A
- Revenue
- EVOK $12,794,859.00
- XXII $21,362,000.00
- Revenue This Year
- EVOK $57.38
- XXII N/A
- Revenue Next Year
- EVOK $59.57
- XXII $126.57
- P/E Ratio
- EVOK N/A
- XXII N/A
- Revenue Growth
- EVOK 70.02
- XXII N/A
- 52 Week Low
- EVOK $1.94
- XXII $1.51
- 52 Week High
- EVOK $12.32
- XXII $613.86
- Technical
- Relative Strength Index (RSI)
- EVOK N/A
- XXII 43.98
- Support Level
- EVOK N/A
- XXII $1.59
- Resistance Level
- EVOK N/A
- XXII $1.77
- Average True Range (ATR)
- EVOK 0.00
- XXII 0.15
- MACD
- EVOK 0.00
- XXII 0.02
- Stochastic Oscillator
- EVOK 0.00
- XXII 15.19
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.